Abbott hit with $70m Illinois verdict in premature infant formula case

A Cook County jury has awarded four families a combined $70 million in damages against Abbott Laboratories after finding that the company’s cow’s milk-based premature infant feeding product caused necrotizing enterocolitis in four premature infants. The verdict included $53 million in compensatory damages and $17 million in punitive damages, according to the source material provided by the user and contemporaneous media reporting on the case.

The case adds to the long-running litigation campaign over premature infant formula products and necrotizing enterocolitis, a serious bowel disease that can affect preterm babies and can involve intestinal inflammation, tissue death, perforation, surgery, and high mortality risk. In this trial, lawyers for the families argued that Abbott knew its product carried a heightened NEC risk for premature infants but failed to provide an adequate warning while continuing to promote the product as safe for use in neonatal intensive care settings.

Abbott has not accepted the verdict as final. Reuters reported that the company plans to appeal and said it believed the jury disregarded the science. That response is important because it shows the legal fight is moving into its next phase rather than ending with this jury decision. The result is therefore significant not only for the four families in Cook County, but also for the broader litigation landscape surrounding hospital-use formula products for premature infants.

Why did the Cook County Abbott verdict matter beyond this one Illinois courtroom?

The Illinois verdict matters because it is not an isolated dispute over a single infant injury claim. Reuters reported that nearly 1,000 lawsuits involving Abbott and Mead Johnson have been filed over similar allegations that cow’s milk-based formula for premature infants increased the risk of necrotizing enterocolitis. Many of those cases are centralized in Illinois federal court, which means outcomes in major state court trials can influence legal expectations, negotiating leverage, media scrutiny, and investor attention even when they do not directly decide other cases.

The Cook County case also stood out because it involved four families in one proceeding, producing a large aggregate award and a punitive damages component. Punitive damages are especially consequential in public and legal terms because they indicate that the jury found more than simple product-related harm. In practical terms, they suggest the jury accepted the plaintiffs’ argument that Abbott’s conduct on warnings and risk communication warranted punishment as well as compensation. Reuters and local reporting both described the split as $53 million in compensatory damages and $17 million in punitive damages.

Another reason the verdict matters is that these cases involve products used in highly sensitive medical settings. Reuters noted that the formulas at issue were intended for hospital use in premature infants rather than for the broader retail formula market. That distinction makes the litigation more consequential for hospitals, neonatal intensive care units, clinicians, risk managers, and insurers because it touches on warning labels, informed consent, feeding protocols, and product liability exposure around medically fragile patients.

What did the families allege about Similac and necrotizing enterocolitis in premature infants?

According to the user-provided source material, the four families alleged that Abbott’s Similac product caused their premature infants to develop necrotizing enterocolitis after use in neonatal intensive care units. Their legal team argued that Abbott knew cow’s milk-based infant feeding products greatly increased the risk of NEC in premature infants and nonetheless marketed the products as safe without sufficiently warning families and providers.

The source material described NEC as a disease involving bacterial invasion of a newborn’s intestinal lining, which can lead to severe inflammation, tissue necrosis, and intestinal perforation. It also stated that the disease often requires surgery and carries a high mortality rate. Those descriptions align with why NEC litigation has become one of the most emotionally and medically sensitive product liability battles in pediatric care.

Media reports on the case show that the families’ lawyers focused heavily on the warning issue. The Chicago Sun-Times reported that the plaintiffs argued Abbott was aware that cow’s milk-based formulas increased NEC risk but failed to warn consumers or healthcare providers. Local coverage also indicated that some jurors believed the product had legitimate uses but that clearer disclosure of the risks should have been provided. That distinction matters because the case, as reflected in reporting, was not simply framed around whether formula has any role in neonatal care. It turned on whether the jury believed Abbott adequately communicated risk in the setting in which the product was used.

How does the Abbott baby formula verdict fit into the wider NEC litigation battle?

The broader NEC litigation has produced mixed outcomes, which makes each large verdict important but not necessarily definitive. Reuters reported that previous trials have delivered a mix of large jury awards and defense wins, with some earlier verdicts under appeal. That means the Cook County verdict strengthens the plaintiffs’ side politically and publicly, but it does not settle the scientific, regulatory, or legal disputes that continue to divide courts and litigants.

One of the key tensions in this litigation is the gap between courtroom outcomes and the state of scientific and regulatory debate. Reuters reported that United States regulatory findings from 2024 suggested the absence of breast milk, rather than formula exposure itself, may be linked to NEC risk. Defendants in these cases, including Abbott, have argued that their products are medically important when breast milk is not available and that some experts support formula as part of care for preterm infants. That means jury verdicts are unfolding against a more contested background than a simple one-way scientific consensus.

At the same time, the plaintiffs’ bar has continued to score enough courtroom wins to keep pressure on manufacturers high. Reuters noted that one prior estimate from analysts had placed potential liability exposure for Abbott in the hundreds of millions to low billions of dollars, though those estimates were shaped by changing trial results and legal developments. Even when such estimates shift, each new plaintiff victory can prolong uncertainty for companies, encourage additional filings, and keep the issue in the headlines.

What does this Illinois jury decision mean for Abbott Laboratories and hospital-use formula disputes?

For Abbott Laboratories, the immediate consequence is reputational, legal, and financial pressure rather than a final payout. Because the company has said it will appeal, the case is likely to remain active. Still, a punitive damages finding can sharpen scrutiny from investors, hospital purchasers, clinicians, and legal observers, especially when it concerns a product used for premature infants in hospital care.

For hospitals and neonatal care providers, the verdict may intensify attention on feeding protocols for premature infants, consent practices, and product-risk communication. Even without any regulatory change announced alongside the verdict, such a case can influence how hospital committees, risk officers, and clinical teams review formula use policies and documentation practices. That is because liability cases often affect institutional behavior before any legislative or regulatory rewrite occurs. This is an inference based on the litigation context and the hospital-use nature of the products at issue.

For the wider public, the verdict underscores that the NEC formula litigation is now large enough to be followed not only as a product liability story but also as a healthcare governance issue. The combination of medical vulnerability, neonatal intensive care use, alleged failure to warn, and large jury awards gives the litigation a policy dimension that extends beyond ordinary consumer claims. In that sense, the Cook County decision is likely to remain part of a wider national debate over how companies communicate risk in highly specialized healthcare settings.

Key takeaways on what this Illinois Abbott NEC verdict means for courts, hospitals, and baby formula litigation

• A Cook County jury awarded four families $70 million against Abbott Laboratories, including $17 million in punitive damages, after finding Abbott’s Similac product caused four premature infants to develop necrotizing enterocolitis.
• Abbott has said it plans to appeal, meaning the Illinois verdict is a major legal development but not the final resolution of the dispute.
• The case sits within a much larger wave of nearly 1,000 lawsuits involving Abbott and Mead Johnson over premature infant formula and necrotizing enterocolitis allegations.
• Because the products at issue were designed for hospital use in premature infants, the verdict carries implications for neonatal intensive care risk communication, hospital protocols, and manufacturer warning practices.
• The litigation remains contested, with mixed trial outcomes and continuing disagreement over how to interpret the scientific and regulatory evidence around formula use and NEC risk.